A new publication involving beinaglutide appeared on August 1, 2026. The paper, titled "Effects of Glucagon-Like Peptide-1 Receptor Agonists (Mono and Combination Therapy) on Energy Expenditure: A Scoping Review," was published in Obesity Reviews, the official journal of the International Association for the Study of Obesity.
The publication is described as a scoping review, a type of study that maps and summarizes existing research on a topic. It examines glucagon-like peptide-1 receptor agonists, used either alone or in combination therapy, in relation to energy expenditure. Beinaglutide is noted among the compounds referenced in this body of work.
No specific findings, outcomes, or conclusions from the review have been provided alongside this listing. The entry reflects only the existence and publication details of the paper, including its title, journal, and date of release.
Beinaglutide remains classified as an unapproved compound under current regulatory status, used only in research contexts. This publication listing does not constitute evidence of safety, efficacy, or approval status for beinaglutide or any other agent discussed in the review.
Readers interested in more background can consult the compound overview for additional context on beinaglutide.